MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11102-024-01479-9

Медицинская библиотека · Pituitary · 2024

IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly.

Chiloiro Sabrina, Giampietro Antonella, Giambò Penelope, Costanza Flavia, Mattogno Pier Paolo, Lauretti Liverana, Calandrelli Rosalinda, Gaudino Simona, Gessi Marco, Rindi Guido, Olivi Alessandro, De Marinis Laura, Doglietto Francesco, Bianchi Antonio, Pontecorvi Alfredo, Giustina Andrea

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

First-generation somatostatin receptor ligands (fg-SRLs) are the cornerstone of acromegaly treatment. Additional benefits were shown using high dose (HD) or high frequency (HF), relatively short-term regimens. Although several predictors of response to standard dose (SD)-fg-SRLs were reported, outcome biomarkers for HF administration are not yet available. Here, we aimed to identify predictors of response to long-term HF-fg-SRLs.

PATIENTS AND

METHODS

A retrospective study was performed on 102 patients, treated with Lanreotide. Patients not controlled at 12 months of SD-Lanreotide (120 mg/28 days) were switched to HF-Lanreotide (120 mg/21 days) for additional 12 months.

RESULTS

Twenty-eight patients were controlled at 6 months of SD-Lanreotide (27.4%); 35 patients were controlled at 12 months of treatment (34.3%). Out of 67 patients treated with HF- Lanreotide, 18 (26.9%) were controlled at 6 months of treatment and remained controlled until 12 months. Both during SD and HF-Lanreotide administrations, IGF-I levels were reduced during the first six months of treatment (p < 0.001), without further significant reduction between 6 and 12 months of therapy. Response at 12 months of SD-Lanreotide was predicted by IGF-I reached at six months of SD-Lanreotide (p = 0.024). Response at 12 months of HF-Lanreotide treatment was predicted by IGF-I levels reached at six months of SD-Lanreotide treatment (p = 0.04) and six months of HF-Lanreotide treatment (p = 0.01).

CONCLUSION

Our results demonstrated that initial IGF-I levels during SD-Lanreotide predicted the biochemical outcome after 12 months of HF-Lanreotide. Patients in whom HF-Lanreotide did not normalize IGF-I after 6 months of treatment remained uncontrolled 12 months after starting this regimen.

Для цитирования: Chiloiro Sabrina, Giampietro Antonella, Giambò Penelope, Costanza Flavia, Mattogno Pier Paolo, Lauretti Liverana, Calandrelli Rosalinda, Gaudino Simona, Gessi Marco, Rindi Guido, Olivi Alessandro, De Marinis Laura, Doglietto Francesco, Bianchi Antonio, Pontecorvi Alfredo, Giustina Andrea. IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly.. Pituitary. 2024. DOI: 10.1007/s11102-024-01479-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.